Cenffitio Liposomal Apigenin Sleep Support Formula with Fisetin, Quercetin, Theaflavins, 60 Softgels

Cenffitio Liposomal Apigenin Softgels provide a 500 mg dose of apigenin delivered through a lipid-based encapsulation system to complement daily wellness routines. Formulated specifically for adults seeking straightforward nighttime alignment, each bottle contains 60 softgels designed for consistent, uncomplicated use.

Nutritional Composition and Delivery Format

• Primary Active Compound: Each softgel supplies 500 mg of apigenin, forming the core foundation of this dietary supplement.
• Liposomal Technology: The capsules incorporate 100 mg of non-GMO sunflower phospholipids to facilitate a stable liposome structure around the botanical extract.
• Complementary Polyphenols: The formulation pairs apigenin with fisetin, quercetin, and theaflavins to deliver a multi-component supplement profile.
• Packaging Quantity: Manufactured as a 60-softgel container to support extended daily regimens without frequent repurchasing.

Routine Integration and Practical Value

Designed to eliminate guesswork from nightly supplementation, these streamlined capsules allow for simple, consistent tracking within an established wellness schedule. Adults who prefer a structured approach to maintaining calm, restful sleep patterns can integrate this formula directly into their existing evening or morning habits. The combination of targeted apigenin concentrations with supportive botanical compounds aims to simplify how consumers manage their daily nutritional intake while reinforcing a dedicated routine.

Usage Guidelines and Form Specification

This supplement is engineered for adult consumption and requires no special preparation, dissolving cleanly upon ingestion. The recommended approach involves taking one softgel daily to maintain steady levels of the active ingredients throughout the week. By combining a high-potency apigenin baseline with sunflower-derived phospholipids and secondary plant extracts, this formula prioritizes straightforward dosing and long-term routine compatibility.